Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

Wu, Jianping; Mao, Weilin

doi:10.1155/2020/2471252

Cited by 9 publications

(5 citation statements)

References 105 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Altogether, it could be speculated that circulating sCD36 might be derived from Further studies are required to clarify the sources of sCD36, as well as to elucidate the mechanisms of CD36 involved in HBV-related liver diseases. Recently, noninvasive liver disease assessments in CHB patients have significantly progressed as several indices, scores or models derived from certain serum biomarkers or their combinations were brought up (Wu and Mao, 2020). These noninvasive indicators, including APRI, FIB-4, homocysteine (Hcy) and others, were proposed to be used in HBV-related liver diseases, such as CHB, HBV-ACLF and HBV-LC.…”

Section: Discussionmentioning

confidence: 99%

“…Recently, noninvasive liver disease assessments in CHB patients have significantly progressed as several indices, scores or models derived from certain serum biomarkers or their combinations were brought up ( Wu and Mao, 2020 ). These noninvasive indicators, including APRI, FIB-4, homocysteine (Hcy) and others, were proposed to be used in HBV-related liver diseases, such as CHB, HBV-ACLF and HBV-LC.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases

Cai

Xiao²,

Luo³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

BackgroundOur previous study suggested CD36 may be a positive regulator of hepatitis B virus (HBV) replication in vitro. Therefore, the present study aimed to investigate whether circulating soluble CD36 (sCD36) could serve as a diagnostic and prognostic biomarker for HBV-related liver diseases based on the clinic collected data.MethodsA total of 282 subjects were divided into healthy controls (HC, n = 47), chronic hepatitis B (CHB, n = 68), HBV-related liver cirrhosis (HBV-LC, n = 167). Soluble CD36 in plasma was measured by ELISA, and monocyte or platelet CD36 expression was determined by flow cytometry.ResultsThere was a step-wise increase of sCD36 with the progression of chronic HBV infection, and it was the highest in the HBV- LC group with liver failure (1.50, IQR:1.04–2.00) as compared with HC (0.38, IQR:0.27–0.38), CHB (0.75, IQR:0.40–1.13), and HBV-LC without liver failure (1.02, IQR,0.61–1.35) group. Circulating sCD36 was not correlated with serum HBV DNA levels, but correlated with liver function parameters. Additionally, ROC analysis confirmed sCD36 could be used to predict liver failure for HBV-LC patients, which yielded an AUC of 0.775 with 71.0% sensitivity and 72.2% specificity. Multivariate logistic regression analysis revealed sCD36 is an independent risk factor in predicting liver failure. Moreover, plasma sCD36 in HBV-LC patients was significantly correlated with prognostic indices, including MELD, MELD-Na and CHILD-PUGH scores. On the other hand, CD36 expression on monocytes or platelets was positively correlated with plasma sCD36 levels, whereas they were not strongly associated with the disease severity.ConclusionCirculating sCD36 could be used as a novel noninvasive biomarker for predicting liver failure and prognosis in chronic HBV infected patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases

Cai

Xiao²,

Luo³

et al. 2022

Front. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The construction of MMIPs-ECS aims to provide theoretical feasibility analysis and practical data to realize the POCT of disease. 118–120 Table 3 summarizes the application of MMIPs-ECS in biomarker detection as reported.…”

Section: Application Of Mmips-cs In Biomarker Detectionmentioning

confidence: 99%

Application progress of magnetic molecularly imprinted polymers chemical sensors in the detection of biomarkers

Wang

Yang

Pang

et al. 2022

Analyst

View full text Add to dashboard Cite

show abstract

“…The natural history of hepatitis B is a dynamic process, traditionally differentiated into five phases depending on virus and host factors, like the state of immune competence, age or the duration of the infection[ 53 ]. They are classified according to liver inflammation data (alanine aminotransferase), determination of hepatitis B e antigen (HBeAg) and quantification of the HBV-DNA viral load[ 54 ] as well as estimation of the degree of hepatic fibrosis, usually by elastography[ 1 ] as serologic indices of fibrosis have proven less precise in HBV infection[ 55 ]. These phases have traditionally been called: immune-tolerant phase, immune-elimination phase, immune-reactive phase, asymptomatic carrier and hepatitis B surface antigen (HBsAg)-negative phase[ 56 ].…”

Section: Hepatitis Bmentioning

confidence: 99%

Present and future management of viral hepatitis

Grande¹,

Leiva²,

Ortega³

et al. 2021

WJG

View full text Add to dashboard Cite

Viral hepatitis can result in important morbidity and mortality, with its impact on health conditioned by the specific type of hepatitis, the geographical region of presentation and the development and access to new drugs, among other factors. Most acute presentation forms are self-limiting and may even go unnoticed, with just a small percentage of cases leading to acute liver failure that may necessitate transplantation or even cause the death of the patient. However, when they become chronic, as in the case of hepatitis B virus and C virus, unless they are diagnosed and treated adequately they may have severe consequences, like cirrhosis or hepatocarcinoma. Understanding of the mechanisms of transmission, the pathogenesis, the presence of vaccinations and the development over recent years of new highly-efficient, potent drugs have meant that we are now faced with a new scenario in the management of viral hepatitis, particularly hepatitis B virus and hepatitis C virus. The spectacular advances in hepatitis C virus treatment have led the World Health Organization to propose the objective of its eradication by 2030. The key aspect to achieving this goal is to ensure that these treatments reach all the more vulnerable population groups, in whom the different types of viral hepatitis have a high prevalence and constitute a niche that may perpetuate infection and hinder its eradication. Accordingly, micro-elimination programs assume special relevance at the present time.

show abstract

Review of Serum Biomarkers and Models Derived from Them in HBV-Related Liver Diseases

Cited by 9 publications

References 105 publications

Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases

Circulating soluble CD36 as a novel biomarker for progression and prognosis of HBV-related liver diseases

Application progress of magnetic molecularly imprinted polymers chemical sensors in the detection of biomarkers

Present and future management of viral hepatitis

Contact Info

Product

Resources

About